Handelsavisen
prelaunch
Companies Healthcare IMA.AX
IM
IMA.AX ASX Biotechnology & Life-Science Tools

Image Resources Nl

A$0,03
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-83,6 %
ROE
-567,5 %
Net margin
-102,8 %
Debt / equity
1,37
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

IMA.AX operates in the Diversified Mining industry, extracting and processing a range of minerals and metals for industrial and commercial applications.

Business. IMA.AX is a diversified mining company operating within the Basic Materials sector, specifically engaged in the extraction and sale of mineral resources. The company is listed on the Australian Securities Exchange (ASX) under the ticker symbol IMA.AX. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the business is described at the industry level as a participant in the diversified mining activity.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target0,10

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
0,10
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-567,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IMA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,7 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Consumer Discretionary+0,4 %+7,7 %−0,2 %
    Information Technology+0,3 %+7,8 %−0,3 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IMA.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    IMA.AX is a diversified mining company operating within the Basic Materials sector, specifically engaged in the extraction and sale of mineral resources. The company is listed on the Australian Securities Exchange (ASX) under the ticker symbol IMA.AX. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the business is described at the industry level as a participant in the diversified mining activity.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    The company's capital structure is highly leveraged, with a debt-to-equity ratio of 1.37, indicating a significant reliance on debt financing. Despite a positive operating cash flow of 7.28 million AUD, the company's free cash flow is negative at -90.87 million AUD, primarily due to capital expenditures of -43.88 million AUD. The current ratio of 0.72 suggests liquidity constraints, as current liabilities exceed current assets.

    Profitability metrics are severely negative, with a return on equity of -5.68 and a return on assets of -0.71, indicating that the company is not generating returns for shareholders or effectively utilizing its assets. Operating income is negative at -67.50 million AUD, and net income is -83.01 million AUD, reflecting a challenging operating environment. These figures are well below the industry median for profitability metrics, suggesting underperformance relative to peers.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases exposure to regional economic and regulatory risks. No specific geographic revenue breakdown is available, but the absence of multiple revenue streams suggests a high concentration risk.

    The company's growth trajectory is negative, with no disclosed revenue growth in the current fiscal year. Analysts have assigned a mean price target of 0.10 AUD, with all recommendations clustered at the "Buy" level, indicating limited optimism about near-term recovery. The absence of positive revenue growth and the negative net income suggest a challenging outlook for the next fiscal year.

    Risk factors include liquidity constraints, with no cash and equivalents and a negative net cash position after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. The company's negative free cash flow and high debt levels suggest a potential need for refinancing or restructuring in the near term.

    Recent events include a negative operating income and net loss, with no disclosed material events or filings in the provided data. The company's financial performance has deteriorated, with a significant drop in profitability and liquidity. No recent transcripts or filings are available to provide additional context on the company's strategic direction or operational challenges.

    Key takeaways
    • IMA.AX is highly leveraged with a debt-to-equity ratio of 1.37, indicating significant financial risk.
    • The company is unprofitable, with a return on equity of -5.68 and a return on assets of -0.71.
    • Liquidity is constrained, with a current ratio of 0.72 and no cash and equivalents.
    • Analysts have assigned a mean price target of 0.10 AUD, with all recommendations at the "Buy" level.
    • The company's revenue is concentrated in a single segment, increasing exposure to regional and industry-specific risks.
    • Negative free cash flow and high debt levels suggest a potential need for refinancing or restructuring.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$0,03
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    A$14.6M
    Net cash
    -A$20.0M
    Current ratio
    0.7
    Debt / equity
    1.4
    ROA
    -70.9%
    ROE
    -5.7%
    Cash conversion
    -9.0%
    CapEx / revenue
    -54.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)IMA 0,0% · rank #64 of 78

    Business relationships

    Business relationships6 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries6
    EX21:21cddaa5b2f4EX21:21cddaa5b2f4Subsidiarie97%
    EX21:23ae86e052d9EX21:23ae86e052d9Subsidiarie97%
    EX21:3267c933be73EX21:3267c933be73Subsidiarie97%
    EX21:a2b8faf9b02bEX21:a2b8faf9b02bSubsidiarie97%
    EX21:bbe4876497bbEX21:bbe4876497bbSubsidiarie97%
    EX21:df3c023405ecEX21:df3c023405ecSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs IMA · multiples and returns
    IQ
    IQV
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    vs self
    Div yield
    vs self
    ROE
    21,9 %
    +58,6 vs self
    CR
    CRL
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -4,6 %
    +32,2 vs self
    ME
    MEDP
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    vs self
    Div yield
    vs self
    ROE
    75,4 %
    +112,2 vs self
    AL
    ALKS
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    vs self
    Div yield
    vs self
    ROE
    8,4 %
    +45,2 vs self
    PI
    PIII
    P3 Health Partners Inc
    $10,02
    72,5M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    95,3 %
    +132,1 vs self
    OR
    ORGO
    Organogenesis Holdings Inc
    $2,34
    301,1M USD
    P/E
    9,0x
    vs self
    Div yield
    vs self
    ROE
    8,5 %
    +45,3 vs self
    NA
    NAGE
    Niagen Bioscience Inc
    $3,45
    274,8M USD
    P/E
    17,4x
    vs self
    Div yield
    vs self
    ROE
    22,7 %
    +59,5 vs self
    SP
    SPRY
    Ars Pharmaceuticals Inc
    $5,46
    542,2M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -149,9 %
    -113,1 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,00
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-08 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,00
    Revenueno estimateno estimate95,4M AUD
    Operating incomeno estimateno estimate6,0M AUD
    Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetA$0,10 · Median A$0,10
    Low A$0,10High A$0,10
    Operating income · consensus6,0M AUD
    EPS surprise
    −7 600,0 %
    reported vs consensus · miss
    Revenue surprise
    −15,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowA$0,10
    MeanA$0,10
    MedianA$0,10
    HighA$0,10
    SpotA$0,03
    +284.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-83,6 %Above median
    Net Margin-102,8 %Above median
    ROE-567,5 %Bottom quartile
    Capex / Rev-54,4 %Bottom quartile
    D/E1,37Bottom quartile
    Cash Conv-0,09Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • IMA.AX Market data — financials · 2026-05-28
    • Image Resources NL Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IMA.AXCanonical
    ASX · AUD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    IMAEX21:21cEX21:23aEX21:326EX21:a2bEX21:bbeEX21:df3Biotechnology
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 56.4%Derived (calculated)
    • Net margin (FY 2025-12-31): -5,668.6%Derived (calculated)
    • Return on equity (FY 2025-12-31): -34.1%Derived (calculated)
    • Return on assets (FY 2025-12-31): -29.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 12.49xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.15xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 680.1%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -24.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -124.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -30.9%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -11.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -77.1%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 182.9%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 860.8%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 13.7%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 56.4%Derived (calculated)
    • EPS (basic) (annual): USD-PER-SHARES -10SEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -10SEC XBRL filing
    • Revenue (annual): USD 800KSEC XBRL filing
    • Pre-tax income (annual): USD -45.7MSEC XBRL filing
    • Total operating expenses (annual): USD 49.25MSEC XBRL filing
    • Total liabilities (annual): USD 19.84MSEC XBRL filing
    • Cash & equivalents (annual): USD 94.53MSEC XBRL filing
    • Operating cash flow (annual): USD -47.84MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-30EVENTQ2 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-17FILING424B3 filing →
    2026-06-17FILING8-K filing →
    2026-06-16 00:00 UTCINSIDER4 insider transactions — 2026-06 4 derivative
    2026-06-16INSIDERStampacchia Otello acquired 15.6k sh Stock Option (right to buy) — Director
    2026-06-16INSIDERWang Jonathan Jian acquired 15.6k sh Stock Option (right to buy) — Director
    2026-06-16INSIDERSLATTERY JOSEPH P acquired 15.6k sh Stock Option (right to buy) — Director
    2026-06-16INSIDERBonita David P acquired 15.6k sh Stock Option (right to buy) — Director
    2026-05-08FILING424B3 filing →
    2026-05-07FILING424B3 filing →
    2026-05-07FILING10-Q filing →
    2026-05-07FILING8-K filing →
    2026-04-30FILINGDEF 14A filing →
    2026-04-14 00:00 UTCINSIDER4 insider transactions — 2026-04 4 derivative
    2026-04-14INSIDERBonita David P acquired 384.7k sh Pre-Funded Warrants (right to buy) — Director
    2026-04-14INSIDERBonita David P acquired 336.6k sh Pre-Funded Warrants (right to buy) — Director
    2026-04-14INSIDERORBIMED ADVISORS LLC acquired 336.6k sh Pre-Funded Warrants (right to buy) — Director
    2026-04-14INSIDERORBIMED ADVISORS LLC acquired 384.7k sh Pre-Funded Warrants (right to buy) — Director
    2026-04-13FILING424B3 filing →
    2026-04-13FILING8-K filing →
    2026-03-17FILING8-K filing →
    2026-03-16 00:00 UTCINSIDER2 insider transactions — 2026-03 1 derivative
    2026-03-16INSIDERYarema Kristin transacted 85.4k sh — Director, Chief Executive Officer
    2026-03-16INSIDERYarema Kristin acquired 128.1k sh Employee Stock Option (right to buy) — Director, Chief Executive Officer
    2026-03-10FILING10-K filing →
    2026-03-10FILING8-K filing →
    2025-12-30 00:00 UTCINSIDER6 insider transactions — 2025-12 4 derivative
    2025-12-30INSIDERButler Erin transacted 22.5k sh — Principal Accounting Officer
    2025-12-30INSIDERButler Erin acquired 22.5k sh Employee Stock Option (right to buy) — Principal Accounting Officer
    2025-12-24INSIDERSLATTERY JOSEPH P bought 16.0k sh — Director ~$96k
    2025-12-18INSIDERWang Jonathan Jian acquired 31.2k sh Employee Stock Option (Right to Buy) — Director
    2025-12-18INSIDERWang Stephen Hui acquired 31.2k sh Employee Stock Option (Right to Buy) — Director
    2025-12-18INSIDERSLATTERY JOSEPH P acquired 31.2k sh Employee Stock Option (Right to Buy) — Director
    2025-07-25 00:00 UTCINSIDER1 insider transaction — 2025-07 · net buy $208k
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage